JP2020529996A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529996A5
JP2020529996A5 JP2020505487A JP2020505487A JP2020529996A5 JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5 JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5
Authority
JP
Japan
Prior art keywords
compound
individual
daily dose
plasma concentration
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045180 external-priority patent/WO2019028360A1/en
Publication of JP2020529996A publication Critical patent/JP2020529996A/ja
Publication of JP2020529996A5 publication Critical patent/JP2020529996A5/ja
Priority to JP2023014110A priority Critical patent/JP2023065372A/ja
Priority to JP2024192836A priority patent/JP2025020292A/ja
Pending legal-status Critical Current

Links

JP2020505487A 2017-08-04 2018-08-03 肥大型心筋症の治療で使用するためのマバカムテン Pending JP2020529996A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023014110A JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023014110A Division JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン

Publications (2)

Publication Number Publication Date
JP2020529996A JP2020529996A (ja) 2020-10-15
JP2020529996A5 true JP2020529996A5 (enExample) 2021-10-07

Family

ID=63350605

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505487A Pending JP2020529996A (ja) 2017-08-04 2018-08-03 肥大型心筋症の治療で使用するためのマバカムテン
JP2023014110A Pending JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A Pending JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023014110A Pending JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A Pending JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20250116181A (enExample)
CN (2) CN111182901A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202134259A (zh) * 2019-11-10 2021-09-16 美商邁奧卡迪亞公司 用肌凝蛋白調節劑之治療方法
CA3165995A1 (en) * 2020-01-28 2021-08-05 Lorena KORDIC Solid state forms of mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
TW202227420A (zh) 2020-11-20 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 三嗪二酮類衍生物、其製備方法及其在醫藥上的應用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
EP4301760A1 (en) 2021-03-04 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PL4370116T3 (pl) * 2021-07-16 2025-04-28 Cytokinetics, Inc. Schematy dawkowania afikamtenu do leczenia obturacyjnej kardiomiopatii przerostowej
EP4404846B1 (en) * 2021-09-24 2025-10-08 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Similar Documents

Publication Publication Date Title
JP2020529996A5 (enExample)
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP6309454B2 (ja) 癌の併用処置
US8697662B2 (en) Methods for treating Kaposi sarcoma
RU2020109345A (ru) Применение мавакамтена для лечения гипертрофической кардиомиопатии
JP6858716B2 (ja) 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
JP2015526458A5 (enExample)
JP5643213B2 (ja) 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤
TW202423423A (zh) 治療非阻塞性肥厚性心肌病之方法
US20240261242A1 (en) Methods of intravenously administering sotalol
Waagstein et al. Clinical results with prenalterol in patients with heart failure
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
CA2753754C (en) Methods for treating schizophrenia
JP6028983B2 (ja) ビダラビンによる心房細動治療
JP7439297B2 (ja) 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法
WO2022125551A1 (en) Method of treating hereditary hemorrhagic telangiectasia using pazopanib
Efanov et al. ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397
RU2022110225A (ru) Применение мавакамтена для лечения гипертрофической кардиомиопатии
Nikolaeva et al. Results of the Cardiological Study Invest: A New Word in the Therapy of Patients with Hypertension
M-Castillo et al. EFFECT OF MANIDIPINE IN CHRONIC KIDNEY DISEASE PATIENTS WITH METABOLIC SYNDROME. PLASENCIA STUDY: PP. 34.399
Ferrara et al. HIGH TG/HDL RATIO HELPS IN THE EVALUATION OF CV RISK OF HYPERTENSIVE PATIENTS WITHOUT METABOLIC SYNDROME: PP. 34.400
JP2005519072A (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとace阻害剤との組み合わせ製剤
HK1152878B (en) Dosing regimen for a selective sip1 receptor agonist
HK1152878A (en) Dosing regimen for a selective sip1 receptor agonist